Results 41 to 50 of about 79,953 (279)

Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis

Frontiers in Immunology, 2022
BackgroundEmerging evidence revealed that gut microbial dysbiosis is implicated in the development of plasma cell dyscrasias and amyloid deposition diseases, but no data are available on the relationship between gut microbiota and immunoglobulin light ...
Jipeng Yan, Jin Zhao, Xiaoxuan Ning, Yunlong Qin, Yan Xing, Yuwei Wang, Qing Jia, Boyong Huang, Rui Ma, Changhui Lei, Meilan Zhou, Zixian Yu, Yumeng Zhang, Wei-Feng Guo, Wei-Feng Guo, Shiren Sun   +15 more
doaj   +1 more source

Human central nervous system (CNS) ApoE isoforms are increased by age, differentially altered by amyloidosis, and relative amounts reversed in the CNS compared with plasma [PDF]

, 2016
The risk of Alzheimer's disease (AD) is highly dependent on apolipoprotein-E (apoE) genotype. The reasons for apoE isoform-selective risk are uncertain; however, both the amounts and structure of human apoE isoforms have been hypothesized to lead to ...
Baker-Nigh, Alaina T, Bateman, Randall J, Bollinger, James G, Cairns, Nigel J, Franklin, Erin E, Holtzman, David, Jiang, Hong, Kasten, Tom, Liao, Fan, Mawuenyega, Kwasi G, Morris, John C, Ovod, Vitaliy   +11 more
core   +3 more sources

AL amyloidosis enhances development of amyloid A amyloidosis [PDF]

British Journal of Dermatology, 2007
Contains fulltext : 52125.pdf (Publisher’s version ) (Open Access)
Hilst, J.C.H. van der, Meer, J.W.M. van der, Drenth, J.P.H., Simon, A.   +3 more
openaire   +1 more source

Impact of Cardiac Disease on Prognosis in Patients with Systemic AL Amyloidosis

Клиническая онкогематология
AIM. To assess the clinical features as well as the factors affecting prognosis and long-term treatment outcomes in systemic AL amyloidosis patients with cardiac involvement. MATERIALS & METHODS. The trial enrolled 123 systemic AL amyloidosis patients
Olga Vladislavovna Pirogova, O. V. Kudyasheva, M. V. Chernous, M. A. Gorodnova, D. K. Lamden, K. A. Novitskaya, A. G. Smirnova, A. V. Yakovleva, V. A. Ionin, A. M. Ananin, I. S. Moiseev, A. D. Kulagin   +11 more
doaj   +1 more source

Review Article of Cardiac Amyloidosis

Walailak Journal of Science and Technology, 2011
Cardiac amyloidosis is a term that means the deposit of abnormal proteins in the myocardium leading to global thickening of the heart walls. The clinical character is that of infiltrative cardiomyopathy.
Jittiporn PURATTANAMAL
doaj   +1 more source

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis

Therapeutic Advances in Hematology, 2021
Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant potential that expresses CD38 molecules on their surface.
Foteini Theodorakakou, Meletios A. Dimopoulos, Efstathios Kastritis   +2 more
doaj   +1 more source

Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis [PDF]

, 2017
Aims: Congo red staining of an endomyocardial biopsy is the diagnostic gold-standard in suspected cardiac amyloidosis (CA), but the procedure is associated with the risk, albeit small, of serious complications, and delay in diagnosis due to the ...
Botcher, N, Fontana, M, Gilbertson, JA, Gillmore, JD, Gonzalez-Lopez, E, Hawkins, PN, Lachmann, HJ, Mahmood, S, Petrie, A, Quarta, CC, Rezk, T, Rowczenio, D, Sachchithanantham, S, Wechalekar, AD, Whelan, CJ, Youngstein, T   +15 more
core   +1 more source

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

Biomarker Research, 2023
Light chain amyloidosis (AL) is a rare disease caused by the generalized deposition of misfolded free light chains. Patients with immunoglobulin M gammopathy (IgM) and indolent B-cell lymphoma such as marginal zone lymphoma (MZL) may in some instances ...
Felix Korell, Stefan Schönland, Anita Schmitt, Madelaine Jansen, Kiavasch Farid, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Ute Hegenbart   +8 more
doaj   +1 more source

Localized AL amyloidosis

Terapevticheskii arkhiv
Localized light chain (AL) amyloidosis (amyloidoma) is a rare disease with unclear pathogenesis and undeveloped approaches to therapy. This article presents 3 clinical observations of localized AL amyloidosis with lesions of the respiratory tract, eyes, and soft tissues of the face.
Nelly A. Kashchavtseva, Irina G. Rekhtina, Alla M. Kovrigina, Tatyana P. Danilina, Larisa P. Mendeleeva   +4 more
openaire   +3 more sources

AL amyloidosis: untangling new therapies

Hematology, 2021
Abstract Systemic light chain (AL) amyloidosis is a protein misfolding disorder characterized by the deposition of abnormal immunoglobulin light chains in fibrillary aggregates, resulting in end-organ damage. Several unique challenges face treating physicians, including delayed diagnosis, advanced vital organ involvement, and morbidity ...
Susan, Bal, Heather, Landau
openaire   +3 more sources